Document and Entity Information
Document and Entity Information - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Mar. 02, 2022 | Jun. 30, 2021 | |
Cover Abstract | |||
Document Type | 10-K | ||
Document Annual Report | true | ||
Document Period End Date | Dec. 31, 2021 | ||
Document Transition Report | false | ||
Entity File Number | 001-38905 | ||
Entity Registrant Name | NextCure, Inc. | ||
Entity Central Index Key | 0001661059 | ||
Entity Incorporation, State or Country Code | DE | ||
Entity Tax Identification Number | 47-5231247 | ||
Entity Address, Address Line One | 9000 Virginia Manor Road, Suite 200 | ||
Entity Address, City or Town | Beltsville | ||
Entity Address, State or Province | MD | ||
Entity Address, Postal Zip Code | 20705 | ||
City Area Code | 240 | ||
Local Phone Number | 399-4900 | ||
Title of 12(b) Security | Common Stock, $0.001 par value per share | ||
Trading Symbol | NXTC | ||
Security Exchange Name | NASDAQ | ||
Entity Well-known Seasoned Issuer | No | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Interactive Data Current | Yes | ||
Entity Filer Category | Non-accelerated Filer | ||
Entity Small Business | true | ||
Entity Emerging Growth Company | true | ||
Entity Ex Transition Period | false | ||
ICFR Auditor Attestation Flag | false | ||
Entity Shell Company | false | ||
Entity Public Float | $ 209 | ||
Entity Common Stock, Shares Outstanding | 27,724,303 | ||
Current Fiscal Year End Date | --12-31 | ||
Document Fiscal Year Focus | 2021 | ||
Document Fiscal Period Focus | FY | ||
Amendment Flag | false | ||
Auditor Name | Ernst & Young LLP | ||
Auditor Firm ID | 42 | ||
Auditor Location | Baltimore, MD |
BALANCE SHEETS
BALANCE SHEETS - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Current assets: | ||
Cash and cash equivalents | $ 12,337 | $ 32,772 |
Marketable securities | 207,254 | 250,676 |
Restricted cash | 39 | 1,706 |
Prepaid expenses and other current assets | 8,187 | 2,824 |
Total current assets | 227,817 | 287,978 |
Property and equipment, net | 13,992 | 15,809 |
Other assets | 577 | 2,857 |
Total assets | 242,386 | 306,644 |
Current liabilities: | ||
Accounts payable | 1,942 | 3,901 |
Accrued liabilities | 4,449 | 4,627 |
Deferred rent, current portion | 217 | 130 |
Term loan, current portion | 1,667 | |
Total current liabilities | 6,608 | 10,325 |
Deferred rent, net of current portion | 2,392 | 792 |
Term loan, net of current portion | 1,806 | |
Total liabilities | 9,000 | 12,923 |
Stockholders' equity | ||
Preferred stock; par value of $0.001 per share; 10,000,000 shares authorized at December 31, 2021 and 2020. No shares issued and outstanding at December 31, 2021 and 2020 | ||
Common stock, par value of $0.001 per share; 100,000,000 shares authorized at December 31, 2021 and 2020, 27,680,997 and 27,568,802 shares issued and outstanding at December 31, 2021 and 2020, respectively | 28 | 28 |
Additional paid-in capital | 421,047 | 410,551 |
Accumulated other comprehensive (loss) income | (663) | 779 |
Accumulated deficit | (187,026) | (117,637) |
Total stockholders' equity | 233,386 | 293,721 |
Total liabilities and stockholders' equity | $ 242,386 | $ 306,644 |
BALANCE SHEETS - (Parenthetical
BALANCE SHEETS - (Parenthetical) - $ / shares | Dec. 31, 2021 | Dec. 31, 2020 | May 13, 2019 |
BALANCE SHEETS | |||
Preferred stock, par value per share | $ 0.001 | $ 0.001 | $ 0.001 |
Preferred stock, number of shares authorized | 10,000,000 | 10,000,000 | 10,000,000 |
Preferred stock, shares issued | 0 | 0 | |
Preferred stock, shares outstanding | 0 | 0 | 0 |
Common stock, par value per share | $ 0.001 | $ 0.001 | $ 0.001 |
Common stock, number of shares authorized | 100,000,000 | 100,000,000 | 100,000,000 |
Common stock, shares issued | 27,680,997 | 27,568,802 | |
Common stock, shares outstanding | 27,680,997 | 27,568,802 | 15,560,569 |
STATEMENTS OF OPERATIONS AND CO
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Revenue: | ||
Revenue from former research and development arrangement | $ 22,378 | |
Revenue, Product and Service [Extensible List] | us-gaap:TechnologyServiceMember | us-gaap:TechnologyServiceMember |
Operating expenses: | ||
Research and development | $ 50,192 | $ 46,554 |
General and administrative | 20,573 | 17,049 |
Total operating expenses | 70,765 | 63,603 |
Loss from operations | (70,765) | (41,225) |
Other income, net | 1,376 | 4,622 |
Net loss | $ (69,389) | $ (36,603) |
Net loss per common share | ||
Basic (in dollars per share) | $ (2.51) | $ (1.33) |
Diluted (in dollars per share) | $ (2.51) | $ (1.33) |
Weighted average shares outstanding | ||
Basic (in shares) | 27,615,977 | 27,532,177 |
Diluted (in shares) | 27,615,977 | 27,532,177 |
Comprehensive loss: | ||
Net loss | $ (69,389) | $ (36,603) |
Unrealized (loss) gain on marketable securities | (1,442) | 779 |
Total comprehensive loss | $ (70,831) | $ (35,824) |
STATEMENTS OF STOCKHOLDERS EQUI
STATEMENTS OF STOCKHOLDERS EQUITY - USD ($) $ in Thousands | Common Stock | Additional Paid-in Capital | Accumulated Other Comprehensive Income (Loss) | Accumulated Deficit | Total |
Balance at the beginning at Dec. 31, 2019 | $ 27 | $ 402,529 | $ (38) | $ (81,034) | $ 321,484 |
Balance at the beginning (in shares) at Dec. 31, 2019 | 27,499,260 | ||||
Increase (Decrease) in Stockholders' Deficit | |||||
Stock based compensation | 7,911 | 7,911 | |||
Exercise of stock options | $ 1 | 111 | 112 | ||
Exercise of stock options (in shares) | 69,542 | ||||
Unrealized gain (loss) on marketable securities, net of tax $0 | 817 | 817 | |||
Net loss | (36,603) | (36,603) | |||
Balance at the end at Dec. 31, 2020 | $ 28 | 410,551 | 779 | (117,637) | $ 293,721 |
Balance at the end (in shares) at Dec. 31, 2020 | 27,568,802 | 27,568,802 | |||
Increase (Decrease) in Stockholders' Deficit | |||||
Stock based compensation | 10,288 | $ 10,288 | |||
Exercise of stock options | 208 | 208 | |||
Exercise of stock options (in shares) | 112,195 | ||||
Unrealized gain (loss) on marketable securities, net of tax $0 | (1,442) | (1,442) | |||
Net loss | (69,389) | (69,389) | |||
Balance at the end at Dec. 31, 2021 | $ 28 | $ 421,047 | $ (663) | $ (187,026) | $ 233,386 |
Balance at the end (in shares) at Dec. 31, 2021 | 27,680,997 | 27,680,997 |
STATEMENTS OF STOCKHOLDERS EQ_2
STATEMENTS OF STOCKHOLDERS EQUITY (Parenthetical) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
STATEMENTS OF STOCKHOLDERS EQUITY | ||
Unrealized gain (loss) on marketable securities, tax expense (benefit) | $ 0 | $ 0 |
STATEMENTS OF CASH FLOWS
STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Cash flows from operating activities: | ||
Net loss | $ (69,389) | $ (36,603) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation, amortization and other | 7,196 | 3,413 |
Stock-based compensation | 10,288 | 7,911 |
Changes in operating assets and liabilities: | ||
Prepaid expenses and other assets | (4,889) | 559 |
Accounts payable | (1,959) | 2,040 |
Accrued liabilities | (178) | (244) |
Deferred rent | 1,687 | 348 |
Deferred revenue | (22,378) | |
Net cash used in operating activities | (57,244) | (44,954) |
Cash flows from investing activities: | ||
Maturities of marketable securities | 195,438 | 187,784 |
Purchases of marketable securities | (156,477) | (137,129) |
Purchase of property and equipment | (2,360) | (7,132) |
Net cash provided by investing activities | 36,601 | 43,523 |
Cash flows from financing activities: | ||
Proceeds from exercise of stock options | 208 | 112 |
Payments of the term loan | (3,473) | (1,527) |
Net cash used in financing activities | (3,265) | (1,415) |
Net decrease in cash, cash equivalents and restricted cash | (23,908) | (2,846) |
Cash, cash equivalents and restricted cash - beginning of period | 36,284 | 39,130 |
Cash, cash equivalents and restricted cash - end of period | 12,376 | 36,284 |
Supplemental disclosures of cash flow information: | ||
Cash paid for interest | $ 162 | 130 |
Supplemental disclosures of noncash investing and financing activities: | ||
Purchase of property and equipment included in accrued liabilities | $ 109 |
Nature of the Business and Basi
Nature of the Business and Basis of Presentation | 12 Months Ended |
Dec. 31, 2021 | |
Nature of the Business and Basis of Presentation | |
Nature of the Business and Basis of Presentation | NEXTCURE, INC. NOTES TO FINANCIAL STATEMENTS 1. Nature of the Business and Basis of Presentation Organization NextCure, Inc. (“NextCure” or the “Company”) was incorporated in Delaware in September 2015 and is headquartered in Beltsville, Maryland. The Company is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Through its proprietary Functional, Integrated, NextCure Discovery in Immuno-Oncology (“FIND-IO”) platform, the Company studies various immune cells in order to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Since inception, the Company has devoted substantially all of its efforts and financial resources to organizing and staffing the Company, identifying business development opportunities, raising capital, securing intellectual property rights related to the Company’s product candidates, building and optimizing the Company’s manufacturing capabilities and conducting discovery, research and development activities for the Company’s product candidates, discovery programs and its FIND-IO platform. Public Offerings of Common Stock On May 13, 2019, the Company closed its initial public offering (“IPO”), in which the Company issued and sold 5,750,000 shares of common stock at a public offering price of $15.00 per share, for net proceeds to the Company of approximately $77.0 million after deducting underwriting discounts and commissions of $6.0 million and offering expenses of $3.4 million. In preparation for the IPO, on May 3, 2019, the Company effected a 1 Upon the closing of the IPO, all of the outstanding shares of the Company’s convertible preferred stock automatically converted into 15,560,569 shares of common stock at the applicable conversion ratio then in effect. Subsequent to the closing of the IPO, there were no shares of preferred stock outstanding. Additionally, the Company’s certificate of incorporation was amended and restated to provide for 100,000,000 authorized shares of common stock with a par value of $0.001 per share and 10,000,000 authorized shares of preferred stock with a par value of $0.001 per share. On November 19, 2019, the Company completed an underwritten public offering, in which the Company issued and sold 4,077,192 shares of common stock at a public offering price of $36.75 per share. On December 2, 2019, the underwriters exercised in full their option to purchase an additional 611,578 shares of common stock at the public offering price of $36.75, for total net proceeds to the Company of $160.9 million after deducting underwriting discounts and commissions of $10.3 million and offering expenses of $1.0 million. Liquidity The Company has not generated any revenue to date from product sales and does not expect to generate any revenues from product sales in the foreseeable future. Through December 2021, the Company has funded its operations primarily with proceeds from public offerings of its common stock, private placements of its preferred stock and upfront fees received under the Company’s former agreement with Eli Lilly and Company (Note 7). The Company expects to incur additional operating losses and negative operating cash flows for the foreseeable future. As of the issuance date of the financial statements for the year ended December 31, 2021, the Company expects that its cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into the first quarter of 2024. The future viability of the Company beyond that date may depend on its ability to raise additional capital to finance its operations. The Company plans to seek additional funding through public or private equity offerings, debt financings, marketing and distribution arrangements, other collaborations, strategic alliances, licensing arrangements or other methods. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliances or other arrangements on favorable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company’s stockholders. If the Company is unable to obtain funding, the Company could be required to delay, reduce or eliminate research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects. Although management continues to pursue these funding plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company, if at all, to fund continuing operations past two years from the issuance date of these financial statements. Risks and Uncertainties The Company is subject to risks common to early-stage companies in the biotechnology industry including, but not limited to: having a limited operating history and no products approved for commercial sale; having a history of significant losses; its need to obtain additional financing; dependence on its ability to advance its current and future product candidates through clinical trials, marketing approval and commercialization; the unproven approach to the discovery and development of product candidates based on the Company’s FIND-IO platform; the lengthy and expensive nature and uncertain outcomes of the clinical development process; the lengthy, time-consuming and unpredictable nature of the regulatory approval process; the results of preclinical studies and early-stage clinical trials that may not be predictive of future results; dependence on its key personnel; its limited manufacturing experience as an organization and with its manufacturing facility; risks related to patent protection and the Company’s pending patent applications; dependence on third-party collaborators for the discovery, development and commercialization of current and future product candidates; and significant competition from other biotechnology and pharmaceutical companies. Pursuit of the Company’s business efforts will require significant amounts of additional capital, adequate personnel, infrastructure and extensive compliance-reporting capabilities. Even if the Company’s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. COVID-19 The impact of the COVID-19 pandemic (including the impact of emerging variant strains of the COVID-19 virus) on the Company’s business and financial performance is uncertain and depends on various factors, including the scope and duration of the pandemic, the efficacy and global distribution of vaccines, government restrictions and other actions, including relief measures, implemented to address the impact of the pandemic, and resulting impacts on the financial markets and overall economy. The imposition of “lockdown,” “social distancing” and “shelter in place” directives and other restrictions on business operations, travel and gatherings by state and federal governments in the United States, as well as governments in other regions of the world in response to the COVID-19 pandemic, has placed significant strain on the Company’s clinical trial sites, has raised concerns around monitoring patient safety, and has caused enrollment to slow in the Company’s clinical trials. Any rise of COVID-19 infection rates, especially in the United States, could continue to negatively affect enrollment going forward. The Company continues to closely monitor the COVID-19 situation and any potential impact to the Company’s planned activities. Segment and Geographic Information Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The chief operating decision maker views the operations and manage the business in one operating segment that operates exclusively in the United States. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2021 | |
Summary of Significant Accounting Policies | |
Summary of Significant Accounting Policies | 2. Summary of Significant Accounting Policies Basis of Presentation The accompanying financial statements include the accounts of the Company. The Company’s financial statements have been prepared in accordance with United States generally accepted accounting principles (‘‘GAAP’’). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (‘‘ASC’’) and Accounting Standards Update (‘‘ASU’’) of the Financial Accounting Standards Board (‘‘FASB’’). Use of Estimates The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the period presented. Although actual results could differ from those estimates, management does not believe that such differences would be material. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. The Company deposits its cash primarily in checking, sweep account and money market accounts. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value. Restricted Cash In August 2021, the Company fully paid the remaining principal balance of $2.4 million of its $5.0 million term loan (the “Term Loan”). As a result of this payment, the Company has no restricted cash held in support of the Term Loan. The required Term Loan reserve totaled $0 and $3.5 million as of December 31, 2021 and 2020, respectively. These amounts are presented in part as restricted cash and in part as other assets on the accompanying balance sheets. The following table reconciles cash and cash equivalents and restricted cash per the balance sheet to the statement of cash flows: December 31, (in thousands) 2021 2020 Cash and cash equivalents $ 12,337 $ 32,772 Restricted cash (including $0 and $1,806 in other assets as of December 31, 2021 and 2020, respectively) 39 3,512 Total $ 12,376 $ 36,284 Marketable Securities Marketable securities primarily consist of government debt securities, corporate bonds and agency bonds. These marketable securities are classified as available-for-sale, and as such, are carried at fair value as determined by prices for identical or similar securities at the balance sheet date. Marketable securities consist of Level 2 financial instruments in the fair-value hierarchy. The Company’s policy is to classify all investments with contractual maturities within one year as current. At each reporting date, the Company evaluates the classification of its investments with maturities beyond one year based on the nature of the investment securities and whether the investments are considered available for use in current operations. Investment income is recognized when earned and reported net of investment expenses. Unrealized holding gains and losses are reported within accumulated other comprehensive income (loss) as a separate component of stockholders’ equity. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and interest on securities are included in other income, net, on the Company’s statements of operations. At each balance sheet date, the Company assesses available-for-sale securities in an unrealized loss position to determine whether the unrealized loss is other-than-temporary. If a decline in the fair value of a marketable security below the Company’s cost basis is determined to be other-than-temporary, such marketable security is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge. The Company considers factors including the significance of the decline in value compared to the cost basis, underlying factors contributing to a decline in the prices of securities in a single asset class, the length of time the market value of the security has been less than its cost basis, the security's relative performance versus its peers, sector or asset class, expected market volatility and the market and economy in general. The Company also evaluates whether it is more likely than not that it will be required to sell a security prior to recovery of its fair value. The cost of securities sold is based on the specific identification method. Concentration of Credit Risk Financial instruments that potentially expose the Company to concentrations of credit risk primarily consist of cash and cash equivalents. The Company maintains its cash and cash equivalents at one accredited financial institution that is federally insured. While balances deposited often exceed federally insured limits, the Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company's investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The counterparties are various corporations, financial institutions and government agencies of high credit standing. Fair Value of Financial Instruments ASC Topic 820, Fair Value Measurement Level 1—Quoted market prices in active markets for identical assets or liabilities. Level 2—Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves. Level 3—Unobservable inputs developed using estimates of assumptions developed by the Company, which reflect those that a market participant would use. Use of these inputs involves significant and subjective judgments to be made by a reporting entity – e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security. To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Property and Equipment, Net Property and equipment are valued at cost less accumulated depreciation. Depreciation is recognized on a straight-line basis over the estimated useful lives of the related assets. Leasehold improvements are amortized on a straight-line basis over the shorter of the useful life or term of the lease. Upon retirement or disposal, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is recorded to general and administrative expenses in the accompanying statement of operations and comprehensive loss. Routine expenditures for maintenance and repairs are expensed as incurred. Estimated useful lives for property and equipment are as follows: Estimated Useful Life Computers and peripherals 3 years Equipment 5 years Furniture and fixtures 7 years Leasehold improvements Lesser of estimated useful life or remaining lease term The Company reviews long-lived assets, which primarily consist of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or group of assets may not be fully recoverable based on the criteria for accounting for the impairment or disposal of long-lived assets under ASC Topic 360, Property, Plant and Equipment. These events or changes in circumstances may include a significant deterioration of operating results, changes in business plans, or changes in anticipated future cash flows. If an impairment indicator is present, the Company evaluates recoverability by comparing the carrying amount of the assets group to future undiscounted net cash flows expected to be generated by the assets group. Assets are grouped at the lowest level for which there is identifiable cash flows that are largely independent of the cash flows generated by other asset groups. If the total of the expected undiscounted future cash flows is less than the carrying amount of the asset, an impairment loss is recognized for the difference between the fair value and carrying value of assets within the group. Fair value is generally determined by estimates of discounted cash flows. The discount rate used in any estimate of discounted cash flows would be the rate required for a similar investment of like risk. No impairment losses were recognized during the years ended December 31, 2021 or 2020. Construction in progress (Note 5) is carried at cost and consists of specifically identifiable direct and indirect development and construction costs. While under construction, costs of the property are included in construction in progress until the property is placed in service, at which time costs are transferred to the appropriate property and equipment account including, but not limited to, leasehold improvements or other such accounts. Leases The Company enters into lease agreements for its office and laboratory facilities and accounts for them in accordance with ASC Topic 840, Leases. These leases are classified as operating leases. Rent expense is recognized on a straight-line basis over the term of the lease and, accordingly, the Company records the difference between cash rent payments and the recognition of rent expense as a deferred rent liability. Incentives granted under the Company’s facilities leases, including allowances to fund leasehold improvements, are deferred and are recognized as adjustments to rental expense on a straight-line basis over the term of the lease. Preferred Stock The Company did not have any outstanding preferred stock as of December 31, 2021 and 2020. Research and Development Costs, Including Clinical Trial Accruals Research costs consist of employee-related costs, contractor expenses, laboratory supplies and facility costs, for research and development of product candidates are expensed as incurred. Development costs, including clinical trial-related expenses, incurred by third parties, such as clinical research organizations (“CROs”), are expensed as the contracted work is performed. Where contingent milestone payments are due to third parties under research and development arrangements, the milestone payment obligations are expensed when the milestone results are probable of being achieved. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Clinical trial expenses are a significant component of research and development expenses, and the Company outsources a significant portion of these costs to third parties. Third-party clinical trial expenses include investigator fees, site and patient costs, CRO costs, and costs for central laboratory testing and data management. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, and other pass-through costs. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the balance sheets as a prepaid asset or accrued expenses. These third-party agreements are generally cancelable, and related costs are recorded as research and development expenses as incurred. Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed. When evaluating the adequacy of the accrued expenses, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. The historical clinical accrual estimates have not been materially different from the actual costs. Patent Costs All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses in the accompanying statement of operations and comprehensive loss. Stock-Based Compensation The Company accounts for its stock-based compensation in accordance with ASC Topic 718, Compensation-Stock Compensation The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (i) the expected stock price volatility, (ii) the expected term of the award, (iii) the risk-free interest rate and (iv) expected dividends. Due to the lack of a public market for the Company’s common stock and lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No. 107, Share-Based Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its employee population. For options granted to non-employees, the Company utilizes the simplified method also as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero because the Company has never paid dividends and has no current plans to pay any dividends on its common stock. The Company recognizes forfeitures as they occur as allowed by ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting There are significant judgments and estimates inherent in the determination of the fair value of the Company’s common stock. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to its common stock at the time of a liquidity event, such as the IPO or a sale, and the likelihood of such an event. The Company expenses the fair value of its share-based compensation awards on a straight-line basis over the requisite service period, which is generally the vesting period. Income Taxes The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base. Deferred tax assets and liabilities, which relate primarily to the carrying amount of the Company’s its net operating loss carryforwards, are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax expense or benefit is the result of changes in the deferred tax assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets where, based upon the available evidence, the Company concludes that it is more-likely-than-not that the deferred tax assets will not be realized. In evaluating its ability to recover deferred tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. Because of the uncertainty of the realization of deferred tax assets, the Company has recorded a full valuation allowance against its deferred tax assets as of December 31, 2021 and 2020. Reserves are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered more-likely-than-not to be sustained on examination by a taxing authority, assuming they possess full knowledge of the position and facts. Interest and penalties related to uncertain tax positions are recognized in the provision of income taxes; however, the Company currently has no interest or penalties related to uncertain income tax benefits. Revenue Recognition The Company accounts for revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC 606, the Company performs the following five steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect consideration to which it is entitled in exchange for the goods or services it transfers to the customer. The Company evaluates customer options for material rights or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer and are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on its own or whether the required expertise is readily available and whether the goods or services are integral to or dependent on other goods or services in the contract. The Company estimates the transaction price based on the amount expected to be received for transferring the goods or services promised in the contract. Consideration generally may include fixed consideration or variable consideration. Should an arrangement include variable consideration, the Company will evaluate the amount of potential payments and the likelihood that the payments will be received. The Company will utilize either the most likely amount method or expected amount method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. The amount of variable consideration that is included in the transaction price may be constrained and will be included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. The Company’s contracts may include development and regulatory milestone payments, which would be assessed under the most likely amount method and constrained if it is probable that a significant revenue reversal would occur. Milestone payments that are not within the Company’s control or the licensee’s control, such as regulatory approvals, will not be considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments would be recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment. For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur and (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). The Company allocates the transaction price based on the estimated stand-alone selling price of each of the performance obligations. The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the stand-alone selling price for service obligations, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs. Additionally, in determining the standalone selling price for material rights, the Company may reference comparable transactions, clinical trial success probabilities and estimates of option exercise likelihood. Variable consideration will be allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated are consistent with the amounts the Company would expect to receive for the satisfaction of each performance obligation. The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Upfront payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current portion of deferred revenue in the accompanying balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion. Amounts are recorded as accounts receivable when the Company’s right to consideration is unconditional. Comprehensive Income (Loss) Comprehensive income (loss) is the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income (loss) includes net income (loss) and the change in accumulated other comprehensive income (loss) for the period. Accumulated other comprehensive income (loss) consisted entirely of unrealized gains and losses on available-for-sale marketable securities at December 31, 2021 and 2020. Net Loss per Share Basic loss per common share is determined by dividing loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted loss per share is computed by dividing the loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company's stock option grants. Recently Issued Accounting Pronouncements The Company qualifies as an emerging growth company (“EGC”) as defined under the Jumpstart Our Business Startups Act (the “JOBS Act”). Using exemptions provided under the JOBS Act provided to EGCs, the Company has elected to defer compliance with new or revised financial accounting standards until it is required to comply with such standards, which is generally consistent with required adoption dates of private companies. In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02 (Topic 842), Leases (“ASC 842”). ASC 842 supersedes the lease recognition requirements in ASC 840, Leases. ASC 842 clarifies the definition of a lease and requires lessees to recognize right-of-use assets and lease liabilities for all leases, including those classified as operating leases under previous lease accounting guidance. For public entities, ASC 842 was effective for fiscal years beginning after December 15, 2018, including interim periods within that year. As a result of the Company having elected the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act, ASC 842 will be effective for the Company on January 1, 2022. Originally, entities were required to adopt ASC 842 using a modified retrospective transition method. However, in July 2018, the FASB issued ASU 2018-11 (Topic 842), Leases: Targeted Improvements, which provides entities with an additional transition method. Under ASU 2018-11, entities have the option of initially applying ASC 842 at the adoption date, rather than at the beginning of the earliest period presented and recognizing the cumulative effect of applying the new standard as an adjustment to beginning retained earnings in the year of adoption while continuing to present all prior periods under previous lease accounting guidance. Based on its current lease portfolio, the Company estimates the adoption of ASC842, using the transition method, will result in approximately $5.8 million of right-of-use assets and $7.2 million of lease liabilities for operating leases being reflected on its balance sheet as of January 1, 2022. The difference between these amounts will be comprised of adjustments related to unamortized balances of deferred rent, lease incentives, and prepaid rent existing as of the effective date. The adoption of the standard is not expected to have a material impact on its statements of operations and comprehensive loss. In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 will require credit losses to be reported using an expected losses model rather than the incurred losses model that is currently used and will require additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard will require allowances to be recorded instead of reducing the amortized cost of the investment. ASU 2016-13 is effective for non-EGCs for fiscal years beginning December 15, 2019, and interim periods within those fiscal years, and will be effective for the Company for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years, assuming the Company remains an EGC. The Company adopted this standard early, effective January 1, 2021. The adoption of this standard did not have a material impact on the Company’s financial statements. The Company considers the applicability and impact of all ASUs issued by the FASB. All other ASUs issued subsequent to the filing of the Company’s Annual Report were assessed and determined to be either inapplicable or not expected to have a material impact on the Company’s financial position or results of operations. |
Marketable Securities
Marketable Securities | 12 Months Ended |
Dec. 31, 2021 | |
Marketable Securities | |
Marketable Securities | 3. Marketable Securities Marketable securities consist of the following: December 31, 2021 Gross Gross Amortized Unrealized Unrealized Estimated (in thousands) Cost Gain Loss Fair Value Corporate bonds $ 207,917 $ 3 $ (666) $ 207,254 Total $ 207,917 $ 3 $ (666) $ 207,254 December 31, 2020 Gross Gross Amortized Unrealized Unrealized Estimated (in thousands) Cost Gain Loss Fair Value Corporate bonds $ 242,900 $ 854 $ (75) $ 243,679 Commercial paper 6,997 — — 6,997 Total $ 249,897 $ 854 $ (75) $ 250,676 As of December 31, 2021, no marketable securities are considered to be other-than-temporarily impaired. The Company uses the specific identification method when calculating realized gains and losses. For the years ended December 31, 2021 and 2020, respectively, the Company recorded $57 thousand and $70 thousand in realized gains on available-for-sale securities, which is included in other income on the statements of operations and comprehensive loss. The following table summarizes maturities of the Company’s investments available-for-sale as of December 31, 2021: December 31, 2021 Fair (in thousands) Cost Value Maturities: Within 1 year $ 104,959 $ 104,775 Between 1 to 2 years 102,958 102,479 Total investments available for sale $ 207,917 $ 207,254 The Company has classified all of its investments available-for-sale, including those with maturities beyond one year, as current assets on the accompanying balance sheets based on the highly liquid nature of these investment securities and because these investment securities are considered available for use in current operations. |
Fair Value Measurements
Fair Value Measurements | 12 Months Ended |
Dec. 31, 2021 | |
Fair Value Measurements | |
Fair Value Measurements | 4. Fair Value Measurements The Company has certain financial assets recorded at fair value, which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements. Level 1—Quoted market prices in active markets for identical assets or liabilities. Level 2—Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves. Level 3—Unobservable inputs developed using estimates of assumptions developed by the Company, which reflect those that a market participant would use. To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The following tables set forth the fair value of the Company’s financial assets by level within the fair value hierarchy as of December 31, 2021 and 2020: December 31, 2021 Significant Quoted Prices in Other Active Markets or Observable Significant Identical Assets Inputs Unobservable (in thousands) Total (Level 1) (Level 2) (Level 3) Cash equivalents: Money market funds $ 2,680 $ 2,680 $ — $ — Marketable securities: Corporate bonds 207,254 — 207,254 — Total $ 209,934 $ 2,680 $ 207,254 $ — December 31, 2020 Significant Quoted Prices in Other Active Markets or Observable Significant Identical Assets Inputs Unobservable (in thousands) Total (Level 1) (Level 2) (Level 3) Cash equivalents: Money market funds $ 11,155 $ 11,155 $ — $ — Marketable securities: Corporate bonds 243,679 — 243,679 — Commercial paper 6,997 — 6,997 — Total $ 261,831 $ 11,155 $ 250,676 $ — The Company did not transfer any assets measured at fair value on a recurring basis between levels during the years ended December 31, 2021 and 2020. The carrying value of financial instruments, including trade receivables, accounts payable and accrued liabilities approximate fair value because of the short-term maturity of these items. The estimated fair values may not represent actual values of the financial instruments that could be realized as of the balance sheet date or that will be realized in the future. |
Property and Equipment, Net
Property and Equipment, Net | 12 Months Ended |
Dec. 31, 2021 | |
Property and Equipment, Net | |
Property and Equipment, Net | 5. Property and Equipment, Net Property and equipment consist of the following: December 31, (in thousands) 2021 2020 Research equipment $ 16,482 $ 13,359 Leasehold improvements 8,566 8,391 Computer equipment 1,143 1,010 Furniture and fixtures 167 113 Construction in progress 371 1,496 Property and equipment, gross 26,729 24,369 Less: accumulated depreciation and amortization (12,737) (8,560) Property and equipment, net $ 13,992 $ 15,809 Construction in progress at December 31, 2021 and 2020 consists of the costs incurred for research equipment and for the build-out of additional lab and office space. Depreciation and amortization expense was $4.3 million and $3.4 million for the years ended December 31, 2021 and 2020, respectively. |
Accrued Liabilities
Accrued Liabilities | 12 Months Ended |
Dec. 31, 2021 | |
Accrued Liabilities | |
Accrued Liabilities | 6. Accrued Liabilities Accrued liabilities consist of the following: December 31, (in thousands) 2021 2020 Construction in progress $ — $ 109 Payroll and related benefits 1,751 973 Clinical trial costs 727 1,744 Sponsored research 1,315 472 Operating expenses 656 1,316 Other — 13 Total accrued liabilities $ 4,449 $ 4,627 |
Former Agreement with Eli Lilly
Former Agreement with Eli Lilly and Company | 12 Months Ended |
Dec. 31, 2021 | |
Former Agreement with Eli Lilly and Company | |
Former Agreement with Eli Lilly and Company | 7. Former Agreement with Eli Lilly and Company On November 2, 2018, the Company entered into a multi-year research and development collaboration agreement (the “Lilly Agreement”) with Eli Lilly and Company (“Lilly”), pursuant to which the Company agreed to use its proprietary FIND-IO platform to identify novel oncology targets for additional collaborative research and drug discovery by the Company and Lilly. Effective March 3, 2020, Lilly, terminated the Lilly Agreement without cause. The Company recognized revenue under the Lilly Agreement of $0 and $22.4 million for the years ended December 31, 2021 and December 31, 2020, respectively. Effective with the termination of the agreement, no further quarterly research and development support payments are payable to the Company. |
Commitments and Contingencies
Commitments and Contingencies | 12 Months Ended |
Dec. 31, 2021 | |
Commitments and Contingencies | |
Commitments and Contingencies | 8. Commitments and Contingencies Operating Leases The Company’s leases primarily comprise real estate for office and manufacturing space. At December 31, 2021, the Company’s minimum obligations under non-cancelable operating leases are as follows: (in thousands) Year Ending December 31, 2022 $ 1,172 2023 1,171 2024 1,231 2025 1,316 Thereafter 6,537 Total future minimum payments $ 11,427 Rent expense incurred under operating leases was $1 million and $0.9 million for the years ended December 31, 2021 and 2020, respectively. Legal Proceedings The Company, from time to time, is a party to litigation or legal proceedings arising in the ordinary course of business. The Company is not a party to any litigation or legal proceedings, nor is management aware of any pending or threatened litigation that, in the opinion of the Company’s management, are likely to have a material adverse effect on the Company’s business. At each reporting date, the Company evaluates whether a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses the costs related to its legal proceedings as incurred. On September 21, 2020, a putative stockholder class action was filed in the U.S. District Court for the Southern District of New York styled Ye Zhou v. NextCure, Inc., et. al., Case 1:20-cv-0772 (S.D.N.Y.). On February 26, 2021, the Lead Plaintiff filed a consolidated amended complaint that asserts claims against us, certain of our officers and members of our board of directors, and the underwriters in our May 2019 initial public offering and November 2019 underwritten secondary public offering. The complaint alleges that the defendants violated provisions of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Securities Act of 1933, as amended, with respect to statements made regarding our lead product candidate, NC318, and the FIND-IO platform. The complaint seeks unspecified damages on behalf of a purported class of purchasers of our securities between May 8, 2019 and July 14, 2020. Defendants filed a motion to dismiss the consolidated amended complaint on April 27, 2021, and discovery is stayed pending resolution of that motion. On March 24, 2021, a purported shareholder derivative lawsuit was filed in the U.S. District Court for the District of Maryland, Southern Division, styled Zach Liu v. Richman et. al., Case:21-cv-00754, alleging breaches of fiduciary duty by officers and/or directors, unjust enrichment, abuse of control, gross mismanagement, waste of corporate assets, and violations of the Exchange Act and the Securities Act of 1933. The Complaint seeks unspecified damages, attorneys’ fees and costs, declaratory relief, corporate governance changes, and restitution. On May 17, 2021, the Court granted the parties’ joint motion to stay the derivative lawsuit pending resolution of the Ye Zhou action’s motion to dismiss. On December 14, 2021, a purported misappropriation of certain trade secrets lawsuit was filed in Federal District Court for the District of Delaware, styled Immunaccel, LLC v. NextCure, Inc., Case No. 1:21-cv-01755-UNA. The lawsuit alleges that the Company misappropriated certain trade secrets belonging to Immunaccel related to a drug discovery and screening platform named IMMUNE 3D. The complaint alleges two causes of action, one under the Delaware Uniform Trade Secrets Act and another under the Federal Defend Trade Secrets Act, and seeks unspecified monetary damages, a permanent injunction and other miscellaneous relief. The Company intends to vigorously defend the Ye Zhou, Liu and Immunaccel actions. Based on the Company’s assessment of the facts underlying these claims, the uncertainty of litigation, and the preliminary stage of these cases, the Company cannot estimate the reasonably possible loss or range of loss that may result from these actions. |
Term Loan
Term Loan | 12 Months Ended |
Dec. 31, 2021 | |
Term Loan | |
Term Loan | 9. Term Loan In April 2016, we entered into a $1.0 million term loan, or the “Term Loan”. In January 2019, we amended the Term Loan to increase our borrowing capacity to $5.0 million, which amount remains secured by our certificates of deposit, money market account, investment property and deposit or investment accounts. In August 2021, we fully paid the remaining principal on the Term Loan, and there are no outstanding payments due from us. |
Preferred Stock
Preferred Stock | 12 Months Ended |
Dec. 31, 2021 | |
Preferred Stock. | |
Preferred Stock | 10. Preferred Stock As of December 31, 2021, the Company’s certificate of incorporation, as amended and restated, authorized the Company to issue 10,000,000 shares of $0.001 par value preferred stock, and there were no shares of preferred stock issued |
Common Stock
Common Stock | 12 Months Ended |
Dec. 31, 2021 | |
Common Stock. | |
Common Stock | 11. Common Stock As of December 31, 2021, the Company’s Certificate of Incorporation, as amended and restated, authorized the Company to issue 100,000,000 shares of $0.001 par value common stock, of which 27,680,997 were issued and outstanding Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any, subject to the preferential dividend rights of any preferred stock. No dividends have been declared or paid by the Company through December 31, 2021. In the event of any liquidation or dissolution of the Company, the holders of common stock are entitled to the remaining assets of the Company legally available for distribution after the payment of the full liquidation preference for any preferred stock. |
Stock-Based Compensation
Stock-Based Compensation | 12 Months Ended |
Dec. 31, 2021 | |
Stock-Based Compensation | |
Stock-Based Compensation | 12. Stock-Based Compensation Employee Equity Plans The NextCure, Inc. 2015 Omnibus Incentive Plan (the “2015 Plan”) was adopted in December 2015 and provides for the grant of awards of stock options, restricted stock awards, unrestricted stock awards and restricted stock units to employees, consultants and directors of the Company. The 2015 Plan is administered by the board of directors or, at the discretion of the board of directors, by a committee of the board of directors. On May 3, 2019, the Company’s stockholders approved the NextCure, Inc. 2019 Omnibus Incentive Plan (as amended, the “2019 Plan”), which became effective on May 8, 2019, the date on which the Company’s Registration Statement on Form S-1 (Reg. No. 333-230837) was declared effective (the “Effective Date”). The Company’s board of directors (the “Board”) determined not to make additional awards under the 2015 Plan following the effectiveness of the 2019 Plan. The 2019 Plan provides for the grant of awards of stock options, stock appreciation rights, restricted stock, restricted stock units, deferred stock units, unrestricted stock, dividend equivalent rights, other equity-based awards and cash bonus awards to the Company’s officers, employees, non-employee directors and other key persons (including consultants). The number of shares of common stock reserved for issuance under the 2019 Plan is 2,900,000 plus the number of shares of stock related to awards outstanding under the 2015 Plan that subsequently terminate by expiration or forfeiture, cancellation or otherwise without the issuance of such shares. The number of shares reserved for issuance under the 2019 Plan will automatically increase each January 1 st st As of December 31, 2021, 2,313,433 shares were reserved for future issuance under the 2019 Plan. Stock options granted under the 2015 Plan and 2019 Plan (together, the “Plans”) to employees generally vest over four years and expire after 10 years. A summary of stock option activity for awards under the Plans is presented below: Options Outstanding and Exercisable Weighted Weighted Average Aggregate Average Remaining Intrinsic Number of Exercise Contractual Value (1) Shares Price Life (Years) (in thousands) Outstanding as of January 1, 2020 2,170,212 $ 6.51 8.6 $ 113,295 Granted 1,115,720 $ 37.08 — — Exercised (69,542) $ 1.84 — — Forfeitures (104,014) $ 25.23 — — Outstanding as of December 31, 2020 3,112,376 $ 16.95 8.2 $ 10,810 Granted 2,020,718 $ 10.89 — — Exercised (105,731) $ 1.62 — — Forfeited (481,569) $ 21.33 — — Outstanding as of December 31, 2021 4,545,794 $ 14.15 8.1 $ 2,860 Exercisable as of December 31, 2021 1,915,494 $ 12.82 7.0 $ 2,783 (1) The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that were in the money at December 31, 2021 and 2020. The weighted average grant date fair value per share of stock options granted during the years ended December 31, 2021 and 2020 was $7.47 and $23.25, respectively. The aggregate intrinsic value of stock options exercised during the years ended December 31, 2021 and 2020 was $469,000 and $633,000, respectively. The aggregate grant date fair value of stock options and restricted stock vested during the year ended December 31, 2021 and 2020 was approximately $13,398,000 and $2,389,000, respectively. On May 3, 2019, the Company’s stockholders approved the NextCure, Inc. 2019 Employee Stock Purchase Plan (the “ESPP”), which became effective on the Effective Date. The ESPP is intended to qualify as an “employee stock purchase plan” within the meaning of Section 423(b) of the Internal Revenue Code. A total of 240,000 shares of common stock were reserved for issuance under this plan. In addition, the number of shares of common stock that may be issued under the ESPP will automatically increase each January 1 st of the ESPP. As of December 31, 2021, 6,464 shares of common stock had been issued pursuant to the ESPP and 784,216 shares were reserved for future issuance thereunder. Stock-Based Compensation The Company recorded stock-based compensation expense of $10.3 million and $7.9 million during the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021, there was $23.3 million of unrecognized compensation cost related to unvested stock-based compensation arrangements granted under the Plans. This remaining compensation expense is expected to be recognized over a weighted-average period of three years as of December 31, 2021. Stock-based compensation expense recorded as research and development and general and administrative expenses is as follows: Year Ended December 31, (in thousands) 2021 2020 Research and development $ 4,081 $ 3,052 General and administrative 6,207 4,859 Total stock-based compensation expense $ 10,288 $ 7,911 The assumptions used in the Black-Scholes option-pricing model for stock options granted were as follows: Year Ended December 31, 2021 2020 Expected term 5.3 - 6.1 years 6.1 years Expected volatility 79.69 % 69.7 - 81.1 % Risk free interest rate 0.8 - 1.4 % 0.3 - 1.0 % Expected dividend yield — % — % |
Net Loss per Share Attributable
Net Loss per Share Attributable to Common Stockholders | 12 Months Ended |
Dec. 31, 2021 | |
Net Loss per Share Attributable to Common Stockholders | |
Net Loss per Share Attributable to Common Stockholders | 13. Net Loss per Share Attributable to Common Stockholders The Company’s potential dilutive securities, which include common stock options, have been excluded from the computation of diluted net loss per share as the effect would be anti-dilutive. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders for the period indicated because including them would have had an anti-dilutive effect: December 31, 2021 2020 Outstanding options to purchase common stock 4,545,794 3,112,376 Total 4,545,794 3,112,376 |
Income Taxes
Income Taxes | 12 Months Ended |
Dec. 31, 2021 | |
Income Taxes | |
Income Taxes | 14. Income Taxes The reconciliation of federal statutory income tax rate to the Company’s effective income tax rate is as follows: December 31, 2021 2020 Expected income tax benefit at the federal statutory rate 21.0 % 21.0 % State taxes, net of federal benefit 6.5 6.5 Research and development credit, net 3.2 7.3 Non-deductible items (1.8) (2.0) Prior year provision to return adjustments (0.4) 0.1 Change in valuation allowance (28.5) (32.9) Total — % — % Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The principal components of the Company’s deferred tax assets consisted of the following as of December 31, 2021 and 2020: December 31, (in thousands) 2021 2020 Deferred tax assets: Federal and state net operating loss carryforwards $ 44,451 $ 28,511 Research and development tax credits 8,862 6,874 Charitable contribution carryforwards 170 306 Share-based compensation 3,184 1,783 Accruals and other 1,121 635 Gross deferred tax assets 57,788 38,109 Less: valuation allowance (57,705) (37,552) Total deferred tax assets $ 83 $ 557 Deferred tax liabilities: Depreciation and amortization $ (83) $ (342) Unrealized gains — (215) Gross deferred tax liabilities $ (83) $ (557) Net deferred tax assets $ — $ — Based on the Company’s history of losses, the Company recorded a full valuation allowance against its deferred tax assets as of December 31, 2021. The Company increased its valuation allowance by approximately $20.2 million for the year ended December 31, 2021. The Company intends to maintain a valuation allowance until sufficient positive evidence exists to support a reversal of the allowance. As of December 31, 2021, the Company had federal and state net operating loss carryforwards of $160.9 million and $163.4 million, respectively, some of which begin to expire in the year ending December 31, 2036. Approximately $138.2 million of the federal net operating loss carryforwards do not expire. The Company had federal and state research and development tax credit carryforwards of approximately $8.7 million and $0.1 million, respectively, as of December 31, 2021. The federal credits begin to expire in the year ending December 31, 2036, and the state credits begin to expire in the year ending December 31, 2024. Under the provisions of Sections 382 and 383 of the Internal Revenue Code (the “IRC”), certain substantial changes in the Company’s ownership may have limited, or may limit in the future, the amount of net operating loss and credit carryforwards that can be used to reduce future income taxes if there has been a significant change in ownership of the Company, as defined by the IRC. Future owner or equity shifts could result in limitations on net operating loss and credit carryforwards. The Company files income tax returns in the U.S. federal jurisdiction as well as in Maryland. The tax years 2017 to 2020 remain open to examination by the major jurisdictions in which the Company is subject to tax. Fiscal years outside the normal statute of limitation remain open to audit by tax authorities due to tax attributes generated in those early years, which have been carried forward and may be audited in subsequent years when utilized. The Company evaluates tax positions for recognition using a more-likely-than-not recognition threshold, and those tax positions eligible for recognition are measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon the effective settlement with a taxing authority that has full knowledge of all relevant information. As of December 31, 2021, the Company had no unrecognized income tax benefits that would affect the Company’s effective tax rate if recognized. The Coronavirus Aid, Relief, and Economic Security Act, or “CARES Act”, and the Consolidated Appropriations Act, 2021, or “Stimulus Bill”, signed into law on March 27, 2020 and December 27, 2020, respectively, have resulted in significant changes to the U.S. federal corporate tax law. Several states have also enacted tax legislation changes. We have considered the applicable tax law changes and determined there was no significant impact to the tax provision of the Company. |
Employee Benefit Plan
Employee Benefit Plan | 12 Months Ended |
Dec. 31, 2021 | |
Employee Benefit Plan | |
Employee Benefit Plan | 15. Employee Benefit Plan The Company sponsors a 401(k) plan which stipulates that eligible employees can elect to contribute to the 401(k) plan, subject to certain limitations, up to the lesser of the statutory maximum or 100% of eligible compensation on a pre-tax basis. For the years ended December 31, 2021 and 2020 the Company did not provide any contributions to this plan. |
Subsequent Events
Subsequent Events | 12 Months Ended |
Dec. 31, 2021 | |
Subsequent Events | |
Subsequent Events | 16. Subsequent Events On February 4, 2022, the Company entered into a Third Amendment to its original Lease Agreement, dated January 30, 2019, whereby the Company has expanded its leased property by approximately 5,700 square feet. |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2021 | |
Summary of Significant Accounting Policies | |
Basis of Presentation | Basis of Presentation The accompanying financial statements include the accounts of the Company. The Company’s financial statements have been prepared in accordance with United States generally accepted accounting principles (‘‘GAAP’’). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (‘‘ASC’’) and Accounting Standards Update (‘‘ASU’’) of the Financial Accounting Standards Board (‘‘FASB’’). |
Use of Estimates | Use of Estimates The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the period presented. Although actual results could differ from those estimates, management does not believe that such differences would be material. |
Cash and Cash Equivalents | Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. The Company deposits its cash primarily in checking, sweep account and money market accounts. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value. |
Restricted Cash | Restricted Cash In August 2021, the Company fully paid the remaining principal balance of $2.4 million of its $5.0 million term loan (the “Term Loan”). As a result of this payment, the Company has no restricted cash held in support of the Term Loan. The required Term Loan reserve totaled $0 and $3.5 million as of December 31, 2021 and 2020, respectively. These amounts are presented in part as restricted cash and in part as other assets on the accompanying balance sheets. The following table reconciles cash and cash equivalents and restricted cash per the balance sheet to the statement of cash flows: December 31, (in thousands) 2021 2020 Cash and cash equivalents $ 12,337 $ 32,772 Restricted cash (including $0 and $1,806 in other assets as of December 31, 2021 and 2020, respectively) 39 3,512 Total $ 12,376 $ 36,284 |
Marketable Securities | Marketable Securities Marketable securities primarily consist of government debt securities, corporate bonds and agency bonds. These marketable securities are classified as available-for-sale, and as such, are carried at fair value as determined by prices for identical or similar securities at the balance sheet date. Marketable securities consist of Level 2 financial instruments in the fair-value hierarchy. The Company’s policy is to classify all investments with contractual maturities within one year as current. At each reporting date, the Company evaluates the classification of its investments with maturities beyond one year based on the nature of the investment securities and whether the investments are considered available for use in current operations. Investment income is recognized when earned and reported net of investment expenses. Unrealized holding gains and losses are reported within accumulated other comprehensive income (loss) as a separate component of stockholders’ equity. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and interest on securities are included in other income, net, on the Company’s statements of operations. At each balance sheet date, the Company assesses available-for-sale securities in an unrealized loss position to determine whether the unrealized loss is other-than-temporary. If a decline in the fair value of a marketable security below the Company’s cost basis is determined to be other-than-temporary, such marketable security is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge. The Company considers factors including the significance of the decline in value compared to the cost basis, underlying factors contributing to a decline in the prices of securities in a single asset class, the length of time the market value of the security has been less than its cost basis, the security's relative performance versus its peers, sector or asset class, expected market volatility and the market and economy in general. The Company also evaluates whether it is more likely than not that it will be required to sell a security prior to recovery of its fair value. The cost of securities sold is based on the specific identification method. |
Concentration of Credit Risk | Concentration of Credit Risk Financial instruments that potentially expose the Company to concentrations of credit risk primarily consist of cash and cash equivalents. The Company maintains its cash and cash equivalents at one accredited financial institution that is federally insured. While balances deposited often exceed federally insured limits, the Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company's investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The counterparties are various corporations, financial institutions and government agencies of high credit standing. |
Fair Value of Financial Instruments | Fair Value of Financial Instruments ASC Topic 820, Fair Value Measurement Level 1—Quoted market prices in active markets for identical assets or liabilities. Level 2—Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves. Level 3—Unobservable inputs developed using estimates of assumptions developed by the Company, which reflect those that a market participant would use. Use of these inputs involves significant and subjective judgments to be made by a reporting entity – e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security. To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. |
Property and Equipment, Net | Property and Equipment, Net Property and equipment are valued at cost less accumulated depreciation. Depreciation is recognized on a straight-line basis over the estimated useful lives of the related assets. Leasehold improvements are amortized on a straight-line basis over the shorter of the useful life or term of the lease. Upon retirement or disposal, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is recorded to general and administrative expenses in the accompanying statement of operations and comprehensive loss. Routine expenditures for maintenance and repairs are expensed as incurred. Estimated useful lives for property and equipment are as follows: Estimated Useful Life Computers and peripherals 3 years Equipment 5 years Furniture and fixtures 7 years Leasehold improvements Lesser of estimated useful life or remaining lease term The Company reviews long-lived assets, which primarily consist of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or group of assets may not be fully recoverable based on the criteria for accounting for the impairment or disposal of long-lived assets under ASC Topic 360, Property, Plant and Equipment. These events or changes in circumstances may include a significant deterioration of operating results, changes in business plans, or changes in anticipated future cash flows. If an impairment indicator is present, the Company evaluates recoverability by comparing the carrying amount of the assets group to future undiscounted net cash flows expected to be generated by the assets group. Assets are grouped at the lowest level for which there is identifiable cash flows that are largely independent of the cash flows generated by other asset groups. If the total of the expected undiscounted future cash flows is less than the carrying amount of the asset, an impairment loss is recognized for the difference between the fair value and carrying value of assets within the group. Fair value is generally determined by estimates of discounted cash flows. The discount rate used in any estimate of discounted cash flows would be the rate required for a similar investment of like risk. No impairment losses were recognized during the years ended December 31, 2021 or 2020. Construction in progress (Note 5) is carried at cost and consists of specifically identifiable direct and indirect development and construction costs. While under construction, costs of the property are included in construction in progress until the property is placed in service, at which time costs are transferred to the appropriate property and equipment account including, but not limited to, leasehold improvements or other such accounts. |
Leases | Leases The Company enters into lease agreements for its office and laboratory facilities and accounts for them in accordance with ASC Topic 840, Leases. These leases are classified as operating leases. Rent expense is recognized on a straight-line basis over the term of the lease and, accordingly, the Company records the difference between cash rent payments and the recognition of rent expense as a deferred rent liability. Incentives granted under the Company’s facilities leases, including allowances to fund leasehold improvements, are deferred and are recognized as adjustments to rental expense on a straight-line basis over the term of the lease. |
Preferred Stock | Preferred Stock The Company did not have any outstanding preferred stock as of December 31, 2021 and 2020. |
Research and Development Costs, Including Clinical Trial Accruals | Research and Development Costs, Including Clinical Trial Accruals Research costs consist of employee-related costs, contractor expenses, laboratory supplies and facility costs, for research and development of product candidates are expensed as incurred. Development costs, including clinical trial-related expenses, incurred by third parties, such as clinical research organizations (“CROs”), are expensed as the contracted work is performed. Where contingent milestone payments are due to third parties under research and development arrangements, the milestone payment obligations are expensed when the milestone results are probable of being achieved. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Clinical trial expenses are a significant component of research and development expenses, and the Company outsources a significant portion of these costs to third parties. Third-party clinical trial expenses include investigator fees, site and patient costs, CRO costs, and costs for central laboratory testing and data management. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, and other pass-through costs. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the balance sheets as a prepaid asset or accrued expenses. These third-party agreements are generally cancelable, and related costs are recorded as research and development expenses as incurred. Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed. When evaluating the adequacy of the accrued expenses, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. The historical clinical accrual estimates have not been materially different from the actual costs. |
Patent Costs | Patent Costs All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses in the accompanying statement of operations and comprehensive loss. |
Stock Based Compensation | Stock-Based Compensation The Company accounts for its stock-based compensation in accordance with ASC Topic 718, Compensation-Stock Compensation The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (i) the expected stock price volatility, (ii) the expected term of the award, (iii) the risk-free interest rate and (iv) expected dividends. Due to the lack of a public market for the Company’s common stock and lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No. 107, Share-Based Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its employee population. For options granted to non-employees, the Company utilizes the simplified method also as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero because the Company has never paid dividends and has no current plans to pay any dividends on its common stock. The Company recognizes forfeitures as they occur as allowed by ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting There are significant judgments and estimates inherent in the determination of the fair value of the Company’s common stock. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to its common stock at the time of a liquidity event, such as the IPO or a sale, and the likelihood of such an event. The Company expenses the fair value of its share-based compensation awards on a straight-line basis over the requisite service period, which is generally the vesting period. |
Income Taxes | Income Taxes The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base. Deferred tax assets and liabilities, which relate primarily to the carrying amount of the Company’s its net operating loss carryforwards, are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax expense or benefit is the result of changes in the deferred tax assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets where, based upon the available evidence, the Company concludes that it is more-likely-than-not that the deferred tax assets will not be realized. In evaluating its ability to recover deferred tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. Because of the uncertainty of the realization of deferred tax assets, the Company has recorded a full valuation allowance against its deferred tax assets as of December 31, 2021 and 2020. Reserves are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered more-likely-than-not to be sustained on examination by a taxing authority, assuming they possess full knowledge of the position and facts. Interest and penalties related to uncertain tax positions are recognized in the provision of income taxes; however, the Company currently has no interest or penalties related to uncertain income tax benefits. |
Revenue Recognition | Revenue Recognition The Company accounts for revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC 606, the Company performs the following five steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect consideration to which it is entitled in exchange for the goods or services it transfers to the customer. The Company evaluates customer options for material rights or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer and are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on its own or whether the required expertise is readily available and whether the goods or services are integral to or dependent on other goods or services in the contract. The Company estimates the transaction price based on the amount expected to be received for transferring the goods or services promised in the contract. Consideration generally may include fixed consideration or variable consideration. Should an arrangement include variable consideration, the Company will evaluate the amount of potential payments and the likelihood that the payments will be received. The Company will utilize either the most likely amount method or expected amount method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. The amount of variable consideration that is included in the transaction price may be constrained and will be included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. The Company’s contracts may include development and regulatory milestone payments, which would be assessed under the most likely amount method and constrained if it is probable that a significant revenue reversal would occur. Milestone payments that are not within the Company’s control or the licensee’s control, such as regulatory approvals, will not be considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments would be recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment. For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur and (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). The Company allocates the transaction price based on the estimated stand-alone selling price of each of the performance obligations. The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the stand-alone selling price for service obligations, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs. Additionally, in determining the standalone selling price for material rights, the Company may reference comparable transactions, clinical trial success probabilities and estimates of option exercise likelihood. Variable consideration will be allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated are consistent with the amounts the Company would expect to receive for the satisfaction of each performance obligation. The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Upfront payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current portion of deferred revenue in the accompanying balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion. Amounts are recorded as accounts receivable when the Company’s right to consideration is unconditional. |
Comprehensive Income (Loss) | Comprehensive Income (Loss) Comprehensive income (loss) is the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income (loss) includes net income (loss) and the change in accumulated other comprehensive income (loss) for the period. Accumulated other comprehensive income (loss) consisted entirely of unrealized gains and losses on available-for-sale marketable securities at December 31, 2021 and 2020. |
Net Loss per Share | Net Loss per Share Basic loss per common share is determined by dividing loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted loss per share is computed by dividing the loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company's stock option grants. |
Recently Issued Accounting Pronouncements | Recently Issued Accounting Pronouncements The Company qualifies as an emerging growth company (“EGC”) as defined under the Jumpstart Our Business Startups Act (the “JOBS Act”). Using exemptions provided under the JOBS Act provided to EGCs, the Company has elected to defer compliance with new or revised financial accounting standards until it is required to comply with such standards, which is generally consistent with required adoption dates of private companies. In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02 (Topic 842), Leases (“ASC 842”). ASC 842 supersedes the lease recognition requirements in ASC 840, Leases. ASC 842 clarifies the definition of a lease and requires lessees to recognize right-of-use assets and lease liabilities for all leases, including those classified as operating leases under previous lease accounting guidance. For public entities, ASC 842 was effective for fiscal years beginning after December 15, 2018, including interim periods within that year. As a result of the Company having elected the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act, ASC 842 will be effective for the Company on January 1, 2022. Originally, entities were required to adopt ASC 842 using a modified retrospective transition method. However, in July 2018, the FASB issued ASU 2018-11 (Topic 842), Leases: Targeted Improvements, which provides entities with an additional transition method. Under ASU 2018-11, entities have the option of initially applying ASC 842 at the adoption date, rather than at the beginning of the earliest period presented and recognizing the cumulative effect of applying the new standard as an adjustment to beginning retained earnings in the year of adoption while continuing to present all prior periods under previous lease accounting guidance. Based on its current lease portfolio, the Company estimates the adoption of ASC842, using the transition method, will result in approximately $5.8 million of right-of-use assets and $7.2 million of lease liabilities for operating leases being reflected on its balance sheet as of January 1, 2022. The difference between these amounts will be comprised of adjustments related to unamortized balances of deferred rent, lease incentives, and prepaid rent existing as of the effective date. The adoption of the standard is not expected to have a material impact on its statements of operations and comprehensive loss. In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 will require credit losses to be reported using an expected losses model rather than the incurred losses model that is currently used and will require additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard will require allowances to be recorded instead of reducing the amortized cost of the investment. ASU 2016-13 is effective for non-EGCs for fiscal years beginning December 15, 2019, and interim periods within those fiscal years, and will be effective for the Company for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years, assuming the Company remains an EGC. The Company adopted this standard early, effective January 1, 2021. The adoption of this standard did not have a material impact on the Company’s financial statements. The Company considers the applicability and impact of all ASUs issued by the FASB. All other ASUs issued subsequent to the filing of the Company’s Annual Report were assessed and determined to be either inapplicable or not expected to have a material impact on the Company’s financial position or results of operations. |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Summary of Significant Accounting Policies | |
Summary of reconciliation cash and cash equivalents and restricted cash per the balance sheet to the statement of cash flows | December 31, (in thousands) 2021 2020 Cash and cash equivalents $ 12,337 $ 32,772 Restricted cash (including $0 and $1,806 in other assets as of December 31, 2021 and 2020, respectively) 39 3,512 Total $ 12,376 $ 36,284 |
Summary of estimated useful lives for property and equipment | Estimated Useful Life Computers and peripherals 3 years Equipment 5 years Furniture and fixtures 7 years Leasehold improvements Lesser of estimated useful life or remaining lease term |
Marketable Securities (Tables)
Marketable Securities (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Marketable Securities | |
Schedule of marketable securities | December 31, 2021 Gross Gross Amortized Unrealized Unrealized Estimated (in thousands) Cost Gain Loss Fair Value Corporate bonds $ 207,917 $ 3 $ (666) $ 207,254 Total $ 207,917 $ 3 $ (666) $ 207,254 December 31, 2020 Gross Gross Amortized Unrealized Unrealized Estimated (in thousands) Cost Gain Loss Fair Value Corporate bonds $ 242,900 $ 854 $ (75) $ 243,679 Commercial paper 6,997 — — 6,997 Total $ 249,897 $ 854 $ (75) $ 250,676 |
Schedule of available-for-sale maturities | December 31, 2021 Fair (in thousands) Cost Value Maturities: Within 1 year $ 104,959 $ 104,775 Between 1 to 2 years 102,958 102,479 Total investments available for sale $ 207,917 $ 207,254 |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Fair Value Measurements | |
Summary of fair value of the Company's financial assets | December 31, 2021 Significant Quoted Prices in Other Active Markets or Observable Significant Identical Assets Inputs Unobservable (in thousands) Total (Level 1) (Level 2) (Level 3) Cash equivalents: Money market funds $ 2,680 $ 2,680 $ — $ — Marketable securities: Corporate bonds 207,254 — 207,254 — Total $ 209,934 $ 2,680 $ 207,254 $ — December 31, 2020 Significant Quoted Prices in Other Active Markets or Observable Significant Identical Assets Inputs Unobservable (in thousands) Total (Level 1) (Level 2) (Level 3) Cash equivalents: Money market funds $ 11,155 $ 11,155 $ — $ — Marketable securities: Corporate bonds 243,679 — 243,679 — Commercial paper 6,997 — 6,997 — Total $ 261,831 $ 11,155 $ 250,676 $ — |
Property and Equipment, Net (Ta
Property and Equipment, Net (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Property and Equipment, Net | |
Summary of property and equipment | December 31, (in thousands) 2021 2020 Research equipment $ 16,482 $ 13,359 Leasehold improvements 8,566 8,391 Computer equipment 1,143 1,010 Furniture and fixtures 167 113 Construction in progress 371 1,496 Property and equipment, gross 26,729 24,369 Less: accumulated depreciation and amortization (12,737) (8,560) Property and equipment, net $ 13,992 $ 15,809 |
Accrued Liabilities (Tables)
Accrued Liabilities (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Accrued Liabilities | |
Summary of accrued liabilities | December 31, (in thousands) 2021 2020 Construction in progress $ — $ 109 Payroll and related benefits 1,751 973 Clinical trial costs 727 1,744 Sponsored research 1,315 472 Operating expenses 656 1,316 Other — 13 Total accrued liabilities $ 4,449 $ 4,627 |
Commitments and Contingencies (
Commitments and Contingencies (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Commitments and Contingencies | |
Schedule of future minimum payments | At December 31, 2021, the Company’s minimum obligations under non-cancelable operating leases are as follows: (in thousands) Year Ending December 31, 2022 $ 1,172 2023 1,171 2024 1,231 2025 1,316 Thereafter 6,537 Total future minimum payments $ 11,427 |
Stock-Based Compensation (Table
Stock-Based Compensation (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Stock-Based Compensation | |
Summary of stock option activity | Options Outstanding and Exercisable Weighted Weighted Average Aggregate Average Remaining Intrinsic Number of Exercise Contractual Value (1) Shares Price Life (Years) (in thousands) Outstanding as of January 1, 2020 2,170,212 $ 6.51 8.6 $ 113,295 Granted 1,115,720 $ 37.08 — — Exercised (69,542) $ 1.84 — — Forfeitures (104,014) $ 25.23 — — Outstanding as of December 31, 2020 3,112,376 $ 16.95 8.2 $ 10,810 Granted 2,020,718 $ 10.89 — — Exercised (105,731) $ 1.62 — — Forfeited (481,569) $ 21.33 — — Outstanding as of December 31, 2021 4,545,794 $ 14.15 8.1 $ 2,860 Exercisable as of December 31, 2021 1,915,494 $ 12.82 7.0 $ 2,783 (1) The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that were in the money at December 31, 2021 and 2020. |
Summary of stock based compensation expense recorded | Year Ended December 31, (in thousands) 2021 2020 Research and development $ 4,081 $ 3,052 General and administrative 6,207 4,859 Total stock-based compensation expense $ 10,288 $ 7,911 |
Summary of assumptions used in the Black Scholes option pricing model for stock options granted | Year Ended December 31, 2021 2020 Expected term 5.3 - 6.1 years 6.1 years Expected volatility 79.69 % 69.7 - 81.1 % Risk free interest rate 0.8 - 1.4 % 0.3 - 1.0 % Expected dividend yield — % — % |
Net Loss per Share Attributab_2
Net Loss per Share Attributable to Common Stockholders (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Net Loss per Share Attributable to Common Stockholders | |
Summary of shares excluded from the computation of diluted net loss per share | December 31, 2021 2020 Outstanding options to purchase common stock 4,545,794 3,112,376 Total 4,545,794 3,112,376 |
Income Taxes (Tables)
Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Income Taxes | |
Summary of reconciliation of federal statutory income tax rate to the Company's effective income tax rate | December 31, 2021 2020 Expected income tax benefit at the federal statutory rate 21.0 % 21.0 % State taxes, net of federal benefit 6.5 6.5 Research and development credit, net 3.2 7.3 Non-deductible items (1.8) (2.0) Prior year provision to return adjustments (0.4) 0.1 Change in valuation allowance (28.5) (32.9) Total — % — % |
Summary of components of deferred tax assets | December 31, (in thousands) 2021 2020 Deferred tax assets: Federal and state net operating loss carryforwards $ 44,451 $ 28,511 Research and development tax credits 8,862 6,874 Charitable contribution carryforwards 170 306 Share-based compensation 3,184 1,783 Accruals and other 1,121 635 Gross deferred tax assets 57,788 38,109 Less: valuation allowance (57,705) (37,552) Total deferred tax assets $ 83 $ 557 Deferred tax liabilities: Depreciation and amortization $ (83) $ (342) Unrealized gains — (215) Gross deferred tax liabilities $ (83) $ (557) Net deferred tax assets $ — $ — |
Nature of the Business and Ba_2
Nature of the Business and Basis of Presentation - Public Offerings and Common Stock (Details) $ / shares in Units, $ in Millions | Dec. 02, 2019USD ($)$ / sharesshares | Nov. 19, 2019$ / sharesshares | May 13, 2019USD ($)$ / sharesshares | May 03, 2019 | Dec. 31, 2021$ / sharesshares | Dec. 31, 2020$ / sharesshares |
Nature of the Business | ||||||
Reverse stock split ratio | 0.1245 | |||||
Issuance of common stock (in shares) | shares | 611,578 | 4,077,192 | ||||
Share price | $ / shares | $ 36.75 | $ 36.75 | ||||
Proceeds from issuance of preferred stock, net of issuance costs | $ | $ 160.9 | |||||
Underwriting discounts and commissions | $ | 10.3 | |||||
Offering expenses | $ | $ 1 | |||||
Common stock, shares outstanding | shares | 15,560,569 | 27,680,997 | 27,568,802 | |||
Preferred stock, shares outstanding | shares | 0 | 0 | 0 | |||
Common stock, number of shares authorized | shares | 100,000,000 | 100,000,000 | 100,000,000 | |||
Common stock, par value per share | $ / shares | $ 0.001 | $ 0.001 | $ 0.001 | |||
Preferred stock, number of shares authorized | shares | 10,000,000 | 10,000,000 | 10,000,000 | |||
Preferred stock, par value per share | $ / shares | $ 0.001 | $ 0.001 | $ 0.001 | |||
IPO | ||||||
Nature of the Business | ||||||
Issuance of common stock (in shares) | shares | 5,750,000 | |||||
Share price | $ / shares | $ 15 | |||||
Proceeds from issuance of shares, net | $ | $ 77 | |||||
Underwriting discounts and commissions | $ | 6 | |||||
Offering expenses | $ | $ 3.4 |
Nature of the Business and Ba_3
Nature of the Business and Basis of Presentation - Liquidity (Details) | 12 Months Ended |
Dec. 31, 2021segment | |
Nature of the Business and Basis of Presentation | |
Number of operating segment | 1 |
Summary of Significant Accoun_4
Summary of Significant Accounting Policies - Restricted Cash (Details) - USD ($) | 1 Months Ended | |||||
Aug. 31, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | Jan. 31, 2019 | Apr. 30, 2016 | |
Restricted Cash | ||||||
Repayment of principal debt balance | $ 2,400,000 | |||||
Face amount | $ 5,000,000 | $ 5,000,000 | $ 1,000,000 | |||
Restricted cash required reserve | 0 | $ 3,500,000 | ||||
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract] | ||||||
Cash and cash equivalents | 12,337,000 | 32,772,000 | ||||
Restricted cash (including $0 and $1,806 in other assets as of December 31, 2021 and 2020, respectively) | 39,000 | 3,512,000 | ||||
Total | 12,376,000 | 36,284,000 | $ 39,130,000 | |||
Other assets, restricted cash | $ 0 | $ 1,806,000 |
Summary of Significant Accoun_5
Summary of Significant Accounting Policies - Property and Equipment (Details) | 12 Months Ended |
Dec. 31, 2021 | |
Computer equipment | |
Property, plant and equipment | |
Property, Plant and Equipment, Estimated Useful Lives | P3Y |
Equipment | |
Property, plant and equipment | |
Property, Plant and Equipment, Estimated Useful Lives | P5Y |
Furniture and fixtures | |
Property, plant and equipment | |
Property, Plant and Equipment, Estimated Useful Lives | P7Y |
Summary of Significant Accoun_6
Summary of Significant Accounting Policies - Additional Information (Details) - USD ($) | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | May 13, 2019 | |
Preferred Stock | |||
Preferred stock, shares outstanding | 0 | 0 | 0 |
Impairment of Long Lived Assets | |||
Impairment loss recognized | $ 0 | $ 0 | |
Income Taxes | |||
Uncertain income tax benefits, interest or penalties | $ 0 |
Summary of Significant Accoun_7
Summary of Significant Accounting Policies - Recently Issued Accounting Pronouncements (Details) - Accounting Standards Update 2016-02 - Cumulative Effect Adjustment - Expected $ in Millions | Dec. 31, 2021USD ($) |
New Accounting Pronouncements or Change in Accounting Principle | |
Operating lease right-of-use assets | $ 5.8 |
Operating lease liabilities | $ 7.2 |
Marketable Securities - (Detail
Marketable Securities - (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Investments | ||
Amortized Cost | $ 207,917,000 | $ 249,897,000 |
Gross Unrealized Gain | 3,000 | 854,000 |
Gross Unrealized Loss | (666,000) | (75,000) |
Estimated Fair Value | 207,254,000 | 250,676,000 |
Marketable securities other-than-temporarily impaired | 0 | |
Gross realized gains | 57,000 | 70,000 |
Cost Maturities: | ||
Within 1 year | 104,959,000 | |
Between 1 to 2 years | 102,958,000 | |
Total investments available for sale | 207,917,000 | |
Fair Value Maturities: | ||
Within 1 year | 104,775,000 | |
Between 1 to 2 years | 102,479,000 | |
Total investments available for sale | 207,254,000 | |
Corporate bonds | ||
Investments | ||
Amortized Cost | 207,917,000 | 242,900,000 |
Gross Unrealized Gain | 3,000 | 854,000 |
Gross Unrealized Loss | (666,000) | (75,000) |
Estimated Fair Value | $ 207,254,000 | 243,679,000 |
Commercial Paper | ||
Investments | ||
Amortized Cost | 6,997,000 | |
Estimated Fair Value | $ 6,997,000 |
Fair Value Measurements - (Deta
Fair Value Measurements - (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Fair value of the Company's financial assets | ||
Marketable Securities | $ 207,254,000 | $ 250,676,000 |
Assets transferred into level 3 | 0 | 0 |
Assets transferred out of level 3 | 0 | 0 |
Assets transferred from level 1 to level 2 | 0 | 0 |
Fair Value | ||
Fair value of the Company's financial assets | ||
Total financial assets | 209,934,000 | 261,831,000 |
Fair Value | Quoted Prices in Active Markets (Level 1) | ||
Fair value of the Company's financial assets | ||
Total financial assets | 2,680,000 | 11,155,000 |
Fair Value | Significant Other Observable Inputs (Level 2) | ||
Fair value of the Company's financial assets | ||
Total financial assets | 207,254,000 | 250,676,000 |
Money market funds (cash equivalents) | Fair Value | ||
Fair value of the Company's financial assets | ||
Money market funds (cash equivalents) | 2,680,000 | 11,155,000 |
Money market funds (cash equivalents) | Fair Value | Quoted Prices in Active Markets (Level 1) | ||
Fair value of the Company's financial assets | ||
Money market funds (cash equivalents) | 2,680,000 | 11,155,000 |
Corporate bonds | Fair Value | ||
Fair value of the Company's financial assets | ||
Marketable Securities | 207,254,000 | 243,679,000 |
Corporate bonds | Fair Value | Significant Other Observable Inputs (Level 2) | ||
Fair value of the Company's financial assets | ||
Marketable Securities | $ 207,254,000 | 243,679,000 |
Commercial Paper | Fair Value | ||
Fair value of the Company's financial assets | ||
Marketable Securities | 6,997,000 | |
Commercial Paper | Fair Value | Significant Other Observable Inputs (Level 2) | ||
Fair value of the Company's financial assets | ||
Marketable Securities | $ 6,997,000 |
Property and Equipment, Net - (
Property and Equipment, Net - (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Property and Equipment, Net | ||
Property and equipment, gross | $ 26,729 | $ 24,369 |
Less: accumulated depreciation and amortization | (12,737) | (8,560) |
Property and equipment, net | 13,992 | 15,809 |
Depreciation and amortization expense | 4,300 | 3,400 |
Research equipment | ||
Property and Equipment, Net | ||
Property and equipment, gross | 16,482 | 13,359 |
Leasehold improvements | ||
Property and Equipment, Net | ||
Property and equipment, gross | 8,566 | 8,391 |
Computer equipment | ||
Property and Equipment, Net | ||
Property and equipment, gross | 1,143 | 1,010 |
Furniture and fixtures | ||
Property and Equipment, Net | ||
Property and equipment, gross | 167 | 113 |
Construction in progress | ||
Property and Equipment, Net | ||
Property and equipment, gross | $ 371 | $ 1,496 |
Accrued Liabilities (Details)
Accrued Liabilities (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Accrued Liabilities | ||
Construction in progress | $ 109 | |
Payroll and related benefits | $ 1,751 | 973 |
Clinical trial costs | 727 | 1,744 |
Sponsored research | 1,315 | 472 |
Operating expenses | 656 | 1,316 |
Other | 13 | |
Total accrued liabilities | $ 4,449 | $ 4,627 |
Former Agreement with Eli Lil_2
Former Agreement with Eli Lilly and Company (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Collaborative Arrangements | ||
Revenue from former research and development arrangement | $ 22,378,000 | |
Lilly Agreement | ||
Collaborative Arrangements | ||
Revenue from former research and development arrangement | $ 0 | $ 22,400,000 |
Commitments and Contingencies -
Commitments and Contingencies - Other (Details) - USD ($) $ in Millions | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Commitments and Contingencies | ||
Rent expenses operating leases | $ 1 | $ 0.9 |
Commitments and Contingencies_2
Commitments and Contingencies - Future Minimum Payments (Details) $ in Thousands | Dec. 31, 2021USD ($) |
Future minimum payments: | |
2022 | $ 1,172 |
2023 | 1,171 |
2024 | 1,231 |
2025 | 1,316 |
Thereafter | 6,537 |
Total future minimum payments | $ 11,427 |
Term Loan - Other (Details)
Term Loan - Other (Details) - USD ($) | Dec. 31, 2021 | Jan. 31, 2019 | Apr. 30, 2016 |
Term Loan | |||
Face amount | $ 5,000,000 | $ 5,000,000 | $ 1,000,000 |
Outstanding balance | $ 0 |
Preferred Stock (Details)
Preferred Stock (Details) - $ / shares | Dec. 31, 2021 | Dec. 31, 2020 | May 13, 2019 |
Preferred Stock. | |||
Preferred stock, number of shares authorized | 10,000,000 | 10,000,000 | 10,000,000 |
Preferred stock, par value per share | $ 0.001 | $ 0.001 | $ 0.001 |
Preferred stock, shares issued | 0 | 0 | |
Preferred stock, shares outstanding | 0 | 0 | 0 |
Common Stock (Details)
Common Stock (Details) | 12 Months Ended | ||
Dec. 31, 2021Vote$ / sharesshares | Dec. 31, 2020$ / sharesshares | May 13, 2019$ / sharesshares | |
Common Stock. | |||
Common stock, number of shares authorized | 100,000,000 | 100,000,000 | 100,000,000 |
Common stock, par value per share | $ / shares | $ 0.001 | $ 0.001 | $ 0.001 |
Common stock, shares issued | 27,680,997 | 27,568,802 | |
Common stock, shares outstanding | 27,680,997 | 27,568,802 | 15,560,569 |
Number of votes per share | Vote | 1 | ||
Dividends declared | $ / shares | $ 0 |
Stock-Based Compensation - Stoc
Stock-Based Compensation - Stock options (Details) - USD ($) | May 03, 2019 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 |
Share Based Compensation Expense Not Recognized | ||||
Unrecognized compensation cost | $ 23,300,000 | |||
Compensation expense recognition period | 3 years | |||
2015 Plan | ||||
Number of Shares | ||||
Outstanding at the beginning (in shares) | 3,112,376 | 2,170,212 | ||
Granted (in shares) | 2,020,718 | 1,115,720 | ||
Exercised (in shares) | (105,731) | (69,542) | ||
Forfeitures (in shares) | (481,569) | (104,014) | ||
Outstanding at the end (in shares) | 4,545,794 | 3,112,376 | 2,170,212 | |
Exercisable at the end (in shares) | 1,915,494 | |||
Weighted Average Exercise Price | ||||
Outstanding at the beginning (in dollars per share) | $ 16.95 | $ 6.51 | ||
Granted (in dollars per share) | 10.89 | 37.08 | ||
Exercised (in dollars per share) | 1.62 | 1.84 | ||
Forfeited (in dollars per share) | 21.33 | 25.23 | ||
Outstanding at the end (in dollars per share) | 14.15 | $ 16.95 | $ 6.51 | |
Exercisable at the end (in dollars per share) | $ 12.82 | |||
Weighted Average Remaining Contractual Life (Years) And Aggregate Intrinsic Value | ||||
Outstanding (in years) | 8 years 1 month 6 days | 8 years 2 months 12 days | 8 years 7 months 6 days | |
Exercisable at the end (in years) | 7 years | |||
Outstanding at the beginning (in dollars) | $ 10,810,000 | $ 113,295,000 | ||
Outstanding at the end (in dollars) | 2,860,000 | $ 10,810,000 | $ 113,295,000 | |
Exercisable at the end (in dollars) | $ 2,783,000 | |||
Weighted average grant date fair value per share of stock options granted | $ 7.47 | $ 23.25 | ||
Aggregate intrinsic value of stock options exercised | $ 469,000 | $ 633,000 | ||
Aggregate grant date fair value | $ 13,398,000 | $ 2,389,000 | ||
Omnibus Incentive Plan | ||||
Stock Based Compensation | ||||
Number of shares reserved for issuance under the plan | 2,900,000 | |||
Annual increase in number of share reserved for issuance (as percent) | 4.00% | |||
2015 Plan and 2019 Employee Stock Purchase Plan | ||||
Stock Based Compensation | ||||
Vesting period | 4 years | |||
Expiration period | 10 years | |||
Number of shares reserved for issuance under the plan | 2,313,433 | |||
2019 Employee Stock Purchase Plan | ||||
Stock Based Compensation | ||||
Number of shares issued | 6,464 | |||
Number of shares reserved for issuance under the plan | 240,000 | 784,216 | ||
Annual increase in number of share reserved for issuance (as percent) | 1.00% | |||
Maximum annual increase in shares available for issuance under the plan | 480,000 |
Stock-Based Compensation - St_2
Stock-Based Compensation - Stock based compensation expense (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Stock based compensation expense | ||
Total stock-based compensation expense | $ 10,288 | $ 7,911 |
Research and development | ||
Stock based compensation expense | ||
Total stock-based compensation expense | 4,081 | 3,052 |
General and administrative | ||
Stock based compensation expense | ||
Total stock-based compensation expense | $ 6,207 | $ 4,859 |
Stock-Based Compensation - Assu
Stock-Based Compensation - Assumptions (Details) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Fair value assumptions | ||
Expected volatility | 79.69% | |
Minimum | ||
Fair value assumptions | ||
Expected term | 5 years 3 months 18 days | 6 years 1 month 6 days |
Expected volatility | 69.70% | |
Risk free interest rate | 0.80% | 0.30% |
Maximum | ||
Fair value assumptions | ||
Expected term | 6 years 1 month 6 days | |
Expected volatility | 81.10% | |
Risk free interest rate | 1.40% | 1.00% |
Net Loss per Share Attributab_3
Net Loss per Share Attributable to Common Stockholders - Anti-dilutive effect (Details) - shares | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Antidilutive Securities | ||
Antidilutive securities excluded from computation of diluted net loss per share | 4,545,794 | 3,112,376 |
Option to purchase common stock | ||
Antidilutive Securities | ||
Antidilutive securities excluded from computation of diluted net loss per share | 4,545,794 | 3,112,376 |
Income Taxes - Reconciliation (
Income Taxes - Reconciliation (Details) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Reconciliation of federal statutory income tax rate to the Company's effective income tax rate | ||
Expected income tax benefit at the federal statutory rate (as a percent) | 21.00% | 21.00% |
State taxes, net of federal benefit (as a percent) | 6.50% | 6.50% |
Research and development credit, net (as a percent) | 3.20% | 7.30% |
Non-deductible items (as a percent) | (1.80%) | (2.00%) |
Prior year provision to return adjustments (as a percent) | (0.40%) | 0.10% |
Change in valuation allowance (as a percent) | (28.50%) | (32.90%) |
Income Taxes - Deferred tax ass
Income Taxes - Deferred tax assets (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Deferred tax assets: | ||
Federal and state net operating loss carryforwards | $ 44,451,000 | $ 28,511,000 |
Research and development tax credits | 8,862,000 | 6,874,000 |
Charitable contribution carryforwards | 170,000 | 306,000 |
Share-based compensation | 3,184,000 | 1,783,000 |
Accruals and other | 1,121,000 | 635,000 |
Gross deferred tax assets | 57,788,000 | 38,109,000 |
Less: valuation allowance | (57,705,000) | (37,552,000) |
Total deferred tax assets | 83,000 | 557,000 |
Deferred tax liabilities: | ||
Depreciation and amortization | (83,000) | (342,000) |
Unrealized gains | (215,000) | |
Gross deferred tax liabilities | (83,000) | $ (557,000) |
Increase in valuation allowance | 20,200,000 | |
Federal net operating loss carryforwards | 160,900,000 | |
State net operating loss carryforwards | 163,400,000 | |
Federal net operating loss carryforwards that do not expire | 138,200,000 | |
Federal research and development tax credit carryforwards | 8,700,000 | |
State research and development tax credit carryforwards | 100,000 | |
Unrecognized income tax benefits | $ 0 |
Employee Benefit Plan (Details)
Employee Benefit Plan (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Employee Benefit Plan | ||
Employer contributions amount | $ 0 | $ 0 |
Subsequent Events - (Details)
Subsequent Events - (Details) | Feb. 04, 2022ft² |
Subsequent Event | |
Subsequent Event | |
Area of office space (in square feet) | 5,700 |